Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

18.30$ +1.1% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Amneal Pharmaceuticals, Inc. (AMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 796 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement AMRX
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	620	617	659	702	702	731	695	725	785	814	723	796	3,118
Cost of Revenue	388	392	421	452	433	468	440	438	511	517	402	462	1,892
Gross Profit	233	225	238	250	270	263	256	286	274	297	320	335	1,226
Research & Development	42	47	39	37	61	56	42	50	63	35	38	41	178
Selling, General & Administrative	113	97	113	116	119	94	118	124	138	146	187	149	620
Total Operating Expenses	157	211	249	154	181	187	156	175	274	183	177	189	823
Operating Income	76	14	-11	95	89	76	100	111	-0.1	115	143	146	403
Interest Expense	51	60	66	66	66	62	57	65	63	56	53	55	227
Pre-Tax Income	23	-83	-76	20	15	-15	37	52	-5.2	55	80	71	201
Income Tax Expense	-2.1	9.9	6.2	3.6	3.7	5.4	13	16	-23	5.7	2.2	1.4	-14
Net Income	9.7	-99	-92	6.0	-0.2	-31	12	22	2.4	35	62	58	157
EBITDA	131	33	46	142	140	112	155	177	112	161	186	194	652

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings